{"id":15451,"date":"2012-09-24T02:30:00","date_gmt":"2012-09-24T00:30:00","guid":{"rendered":"http:\/\/www.fedaiisf.it\/big-pharma-in-fuga-dalla-ricerca-su-alzheimer\/"},"modified":"2012-09-24T02:30:00","modified_gmt":"2012-09-24T00:30:00","slug":"big-pharma-in-fuga-dalla-ricerca-su-alzheimer","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/big-pharma-in-fuga-dalla-ricerca-su-alzheimer\/","title":{"rendered":"Big Pharma on the run from Alzheimer's research"},"content":{"rendered":"

With populations aging and dementia cases multiplying, Alzheimer's looked like a promising investment opportunity for pharmaceutical companies. But now, highlights an analysis in the Independent, the drug giants seem to be having second thoughts: the failure of a series of studies on promising drug candidates, which proved to be ineffective, has led many companies to judge the search for a cure for dementia too difficult and expensive. <\/p>\n

<\/font><\/span><\/p>\n

At least five studies in the last five years have produced disappointing results. A Pfizer-backed trial of Dimebon this year showed no benefit. With something like $750 million in investment lost by the company. In July, then bapineuzumab, developed by Elan in collaboration with Pfizer and J&J, did not show an impact on the symptoms of the disease. A disappointment experienced in August by Eli Lilly, who reported the failure of solanezumab, the second 'flop' anti-Alzheimer's drug in two years. <\/p>\n

<\/font><\/span><\/p>\n

In 2010, then, tests on semagacestat even showed a worsening of symptoms. A series of missteps that have dealt a serious blow to the confidence of drug makers in the field of neuroscience.<\/p>\n

<\/font><\/span><\/p>\n

Result? The recession has put pressure on pharmaceutical makers worldwide, but neurosciences have been hit hard, with AstraZeneca, Pfizer, Merck, Sanofi, Novartis and GSK downsizing European departments. <\/p>\n

<\/font><\/span><\/p>\n

Speaking at a conference organized by the UK's Science Media Centre, Eric Karran, research director at Alzheimer Research GB, stressed that 'neuroscience is a very challenging area. All companies are losing jobs, but neuroscience has the highest attrition rate.'<\/p>\n

<\/font><\/span><\/p>\n

Margherita Lopes \u2013 <\/span><\/i>September 24, 2012 \u2013 PharmaKronos<\/span><\/i><\/p>\n

<\/span><\/p>\n

 <\/p>","protected":false},"excerpt":{"rendered":"

Con l’invecchiamento della popolazione e il moltiplicarsi dei casi di demenza, l’Alzheimer sembrava un’opportunità d’investimento promettente per le aziende farmaceutiche. Ma ora, evidenzia un’analisi sull’Independent, i colossi del farmaco sembrano ripensarci: il fallimento di una serie di studi su candidati farmaci promettenti, rivelatisi inefficaci, ha portato molte aziende a giudicare la ricerca di una cura …<\/p>","protected":false},"author":1,"featured_media":9846,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[90],"tags":[],"class_list":["post-15451","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-fedaiisf-archivio-storico"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/15451","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=15451"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/15451\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/9846"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=15451"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=15451"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=15451"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}